Table 1 General characteristics of the study cohort at inclusion
Variable | Control group | Prone group |
|---|---|---|
Count | 39 | 36 |
Male | 32 (82%) | 23 (64%) |
Age | 65 [55–70] | 66 [53–74] |
BMI | 29 [27–33] | 28 [25–30] |
Obesity (BMI ≥ 30 kg m−2) | 12 (32%) | 8 (23%) |
Hypertension | 21 (55%) | 17 (47%) |
Ischemic cardiac disease | 5 (13%) | 6 (17%) |
Congestive heart failure | 6 (15%) | 2 (6%) |
Lung disease | 10 (26%) | 4 (11%) |
Asthma | 5 (13%) | 1 (3%) |
COPD | 4 (10%) | 2 (6%) |
Fibrosis | 0 (0%) | 1 (3%) |
Sarcoidosis | 1 (3%) | 0 (0%) |
Diabetes mellitus | 11 (28%) | 14 (39%) |
Renal diseasea | 2 (5%) | 3 (8%) |
Active cancer | 1 (3%) | 4 (11%) |
Liver disease | 1 (3%) | 0 (0%) |
Enrollment outside ICU | 20 (51%) | 19 (53%) |
HFNO | 29 (74%) | 31 (86%) |
Flow rate (HFNO) | 50 [40–50] | 50 [40–50] |
PEEP (NIV) | 8 [6–8] | 7 [6–10] |
FiO2 | 0.6 [0.55–0.70] | 0.6 [0.55–0.70] |
SpO2 | 94 [92–95] | 93 [91–94] |
PaO2 | 9.2 [8.2–10] | 8.8 [7.7–9.7] |
RR | 26 [23–32] | 24 [21–29] |
PaO2/FiO2 ratio | 15.4 [12.5–17.3] | 15.4 [11.5–17.4] |
SpO2/FiO2 ratio | 157 [136–175] | 151 [131–174] |
SBP | 130 [120–140] | 130 [120–140] |
DBP | 70 [60–80] | 69 [62–75] |